Grant ID DP160057
Awarded On November 16, 2016
Title Clinical Evaluation of a Novel T Cell Therapy (BPX-501) for the Treatment of Children and Adults with AML
Program Product Development Research
Award Mechanism Texas Company Product Development Awards
Institution/Organization Bellicum Pharmaceuticals, Inc.
Principal Investigator/Program Director Melissa Aldinger
Cancer Sites Leukemia
Contracted Amount $16,946,716
Lay Summary

Many patients with leukemia are cured by a stem cell transplant after intense chemotherapy. However, cancer relapse, infection, and graft versus host (GvHD) are common in the months after a transplant. The problem is that harmful T cells in the transplant cannot be separated from essential, helpful T cells that kill residual cancer and help stem cells become established. Harmful T cells attack the skin, intestines, and the liver, which they see as foreign. For these reasons, many cancer patients without a matched donor cannot receive a transplant, and those that do risk severe, often fatal complications.

Bellicum Pharmaceuticals has developed a revolutionary new T-cell therapy (BPX-501) t...

Read More